Lazarus Effect, a Campbell, Calif.-based medical device company focused on the development of novel interventional devices to facilitate removal of blood clots, closed a $5m financing.
The proceeds will support EU commercialization of several approved devices, as well as regulatory filings for the Lazarus ReCover™ and Lazarus Cover™ in the United States.
Led by Martin Dieck, chairman and CEO, Lazarus Effect is developing a complete portfolio of vascular-device products to facilitate removal of blood clots based on a patented, wire-frame technology platform.
The company currently has five issued US patents and numerous pending US and worldwide patent applications. The Lazarus Funnel™ Guide Catheter and Lazarus ReCover devices have CE Mark for use in Europe, and the Funnel is cleared for use in the United States.
The Lazarus Cover is pending CE Mark. Neither the ReCover nor the Cover are approved for sale in the United States.